Google Übersetzer
Intellia Therapeutics, Inc.
About
Intellia Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 27 2026
Intellia Announces Proposed Public Offering of Common Stock
Apr 27 2026
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
Apr 27 2026
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
Apr 24 2026
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
Mar 3 2026
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
Recent Videos
Gene and Cell Therapy Update – 30 Apr 2026: Otarmeni Approval, Kelonia Deal and More
Apr 30, 2026
Intellia’s CRISPR Cure Crushes Phase 3: NTLA Soars! NTLA Stock Analysis
Apr 29, 2026
Gene Therapy Weekly: CRISPR's Biggest Trial Result Yet | GENEration Hope #Shorts
Apr 28, 2026
Intellia Therapeutics (NTLA): 🧬 The First CRISPR Phase 3 Success
Apr 28, 2026